Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Kepler Cheuvreux analyst Aymeric Poulain downgraded Saab (SAABF) to Reduce from Hold with a price target of SEK 275, up from SEK 245. The ...

Kepler Cheuvreux initiated coverage on Nexity (EPA:NEXI) SA (NXI:FP), a prominent player in the French real estate market, assigning a Hold rating to the company's shares. The research firm has ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

“Unigestion brings its quantitative and qualitative public equities expertise, enhancing Kepler Cheuvreux’s well-established research capabilities. This partnership merges fundamental and quantitative ...

Kepler Cheuvreux’s David Evans, who previously described hype around obesity drugs as a “bubble,” said his concerns around competition and pricing are now factored into Novo’s stock price.

On Thursday, Kepler Cheuvreux analyst David Evans upgraded Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock from Hold to Buy, adjusting the price target to DKK630.00, down from the previous DKK715.00.

The competition for arranging shipping deals in the Nordic investment bank market is heating up. On Tuesday, Norwegian ...

On Tuesday, Kepler Cheuvreux analyst Rasmus Engberg reinstated coverage ... investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro. Engberg's commentary ...

Kepler Cheuvreux has also analyzed BBVA's hedging policy in its ... along with over 1,400 detailed Pro Research Reports, available exclusively on InvestingPro. In other recent news, Banco Bilbao ...